Polymeric treatment compositions

Patent metadata

Field	Value
Publication number	US-9655989-B2
Application number	US-201514736145-A
Country	US
Kind code	B2
Filing date	Jun 10, 2015
Priority date	Oct 15, 2012
Publication date	May 23, 2017
Grant date	May 23, 2017

Abstract

Polymeric compositions are described comprising a biocompatible polymer including a biodegradable linkage to a visualization agent and a non-physiological pH solution; wherein the biocompatible polymer is soluble in the non-physiological pH solution and insoluble at a physiological pH. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use.

First claim

We claim:

1. A polymer including:
a biodegradable linkage to a visualization agent wherein the visualization agent is formed from a monomer having at least one aromatic ring and at least one polymerizable moiety,
wherein the polymer is substantially stable and wherein the polymer is soluble in a non-physiological solution and insoluble in a physiological solution,
wherein substantially stable is where the polymer is greater than 90% intact after about 1 month after an implantation procedure.

2. The polymer of claim 1 , wherein the biodegradable linkage is Seq. ID 1, Seq. ID 2, Seq. ID 3, Seq. ID 4, Seq. ID 5, Seq. ID 6, Seq. ID 7, Seq. ID 8, Seq. ID 9, Seq. ID 10, Seq. ID 11, Seq. ID 12, or Seq. ID 13.

3. The polymer of claim 1 , wherein the biodegradable linkage is an ester or a polyester.

4. The polymer of claim 1 , wherein a monomer included in the polymer is 2-oxo-2-(1-oxo-1-(1-oxo-1-(2,4,6-triiodophenoxy)propan-2-yloxy)propan-2-yloxy)ethoxy)ethyl acrylate.

5. The polymer of claim 1 including a monomer including at least one hydroxyl group.

6. The polymer of claim 5 , wherein the monomer is an acrylate.

7. The polymer of claim 6 , wherein the acrylate is hydroxyethyl methacrylate.

8. The polymer of claim 1 , wherein the non-physiological solution is dimethyl formamide.

9. The polymer of claim 1 , wherein the non-physiological solution is dimethyl sulfoxide.

10. The polymer of claim 1 including a reaction product of between about 75% and about 98% 2-oxo-2-(1-oxo-1-(1-oxo-1-(2,4,6-triiodophenoxy)propan-2-yloxy)propan-2-yloxy)ethoxy)ethyl acrylate, between about 2% and about 25% hydroxyethyl methacrylate, and less than 1% azobisisobutyronitrile.

11. The polymer of claim 1 including a reaction product of between about 85% and about 98% 1-((2-(methacryloyloxy)ethoxy)carbonyloxy) ethyl 3,5-diacetamido-2,4,6-triiodobenzoate, between about 2% and about 15% hydroxyethyl methacrylate, and less than 1% azobisisobutyronitrile.

12. The polymer of claim 1 , wherein substantially stable is where the polymer is greater than 60% intact after about 1 year after the implantation procedure.

13. The polymer of claim 1 , wherein substantially stable is where the polymer is greater than 60% intact after about 5 years after the implantation procedure.

14. The polymer of claim 1 , wherein substantially stable is where the polymer is greater than 90% intact after about 2 months after the implantation procedure.

15. The polymer of claim 1 , wherein substantially stable is where the polymer is greater than 80% intact after about 6 months after the implantation procedure.

Assignees

• Microvention Inc

Inventors

• Cruise Gregory M
• Constant Michael J
• Keeley Edward Michael
• Greene Rob
• Harris Clayton

Classifications

• A61P7/04

  Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61L24/06 Primary

  obtained by reactions only involving carbon-to-carbon unsaturated bonds {(A61L24/043, A61L24/046 take precedence)} · CPC title

• A61K49/0442

  Polymeric X-ray contrast-enhancing agent comprising a halogenated group · CPC title

• A61L2300/44

  Radioisotopes, radionuclides · CPC title